Composite prebiotics and application thereof

The intestinal barrier is repaired through the components such as chicken gizzard, hawthorn, and plum juice concentrate in the compound prebiotic formula, and the problem of sorbitol destroying intestinal health is solved, achieving effective effect of relieving constipation and significantly improving the water content of feces. and small intestine propulsion rate to reduce intestinal damage and avoid side effects.

CN118902083APending Publication Date: 2024-11-08SHANDONG YINGBEIJIAN FOOD TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411063978.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing prebiotic products often contain sorbitol. Long-term use may damage the intestinal barrier, affect intestinal health, lead to side effects, and be difficult to effectively relieve constipation.

Method used

Provides a complex prebiotic formula including chicken gizzard, hawthorn, plum juice concentrate, xylooligosaccharide, sedrosolic, mannose oligosaccharide, galactomannan, resistant dextrin and polyglucose, through repair The intestinal barrier function avoids the side effects of sorbitol and is used to prepare intestinal laxative products to relieve constipation.

Benefits of technology

This compound prebiotic formula significantly increases the water content of feces, small intestine propulsion rate, regulates gastrointestinal transmitters, reduces intestinal barrier damage caused by constipation, avoids the side effects of sorbitol diarrhea, and provides a long-term effect of relieve constipation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902083A_ABST
    Figure CN118902083A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of functional foods and beverages, and particularly relates to compound prebiotics and application thereof. The compound prebiotics comprise the following components in parts by weight: 2-4 parts of endothelium corneum gigeriae galli, 2-4 parts of haws, 2-5 parts of prune concentrated juice, 2-4 parts of xylooligosaccharide, 2-4 parts of stachyose, 0-0.1 part of mannan-oligosaccharide, 6-10 parts of galactooligosaccharide, 0-0.1 part of galactomannan, 0-0.5 part of resistant dextrin and 0-2 parts of polydextrose. According to the compound prebiotic product, under the compounding effect of all the components, constipation can be effectively relieved in a way of repairing the intestinal barrier function; moreover, the formula does not contain sorbitol, so that side effects caused by diarrhea due to long-time use of sorbitol are avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of functional food and beverage, and specifically relates to a composite prebiotic and application thereof. Background Art

[0002] Constipation is a common digestive system problem. Data from the "Chinese Expert Consensus on Chronic Constipation (2019)" shows that about 50 million adults in my country suffer from constipation, and the severity of constipation varies from person to person. Mild constipation may only manifest as poor defecation, dry or hard stools, and patients may feel slight abdominal discomfort. However, when constipation symptoms continue to worsen, problems such as abdominal distension, abdominal pain, and loss of appetite may occur. These symptoms not only affect the patient's daily life, but may also have a negative impact on their mental health, causing emotional problems such as insomnia, irritability, and depression.

[0003] Prebiotics are a special type of dietary fiber that cannot be fully absorbed and utilized by the human body. The undigested part will enter the colon and be decomposed and utilized by the intestinal flora. Prebiotics that enter the colon can feed the intestinal flora and further produce a prebiotic effect. The beneficial effects of prebiotics that have been discovered so far include promoting the increase of beneficial bacteria, inhibiting harmful bacteria, short-chain fatty acids, increasing fecal water content, and softening feces. At the same time, prebiotics can be extracted from natural foods, are basically non-toxic and harmless, have few side effects, and have long-lasting effects. The excellent properties of prebiotics make them an effective means of treating constipation.

[0004] However, sorbitol is often added to prebiotic products on the market. Long-term use of sorbitol may damage the intestinal barrier and affect intestinal health. It is necessary to avoid the use of sorbitol in beverages that are consumed for a long time as much as possible.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide a composite prebiotic and its application; the composite prebiotic product can effectively relieve constipation by repairing the intestinal barrier function under the compounding effect of various components; and the formula does not contain sorbitol, thereby avoiding the side effects caused by long-term use of sorbitol for catharsis.

[0007] In order to overcome the deficiencies of the prior art, the present invention provides the following technical solutions:

[0008] A composite prebiotic comprises the following components by weight: 2-4 parts of chicken gizzard lining, 2-4 parts of hawthorn, 2-5 parts of prune concentrate, 2-4 parts of xylo-oligosaccharide, 2-4 parts of stachyose, 0-0.1 parts of manno-oligosaccharide, 6-10 parts of galacto-oligosaccharide, 0-0.1 parts of galacto-mannan, 0-0.5 parts of resistant dextrin and 0-2 parts of polydextrose.

[0009] Furthermore, the following components are included by weight: 3 parts of chicken gizzard lining, 3 parts of hawthorn, 3.5 parts of prune concentrate, 3 parts of xylo-oligosaccharides, 3 parts of stachyose, 0.05 parts of manno-oligosaccharides, 8 parts of galacto-oligosaccharides, 0.05 parts of galactomannan, 0.1 parts of resistant dextrin and 1 part of polydextrose.

[0010] Furthermore, the soluble solid content in the prune concentrated juice is 60-70%.

[0011] In addition, the present invention also provides the use of the above-mentioned composite prebiotics in the preparation of a laxative product.

[0012] Furthermore, the laxative effect includes at least one of the following functions:

[0013] (1) Increase the water content of feces;

[0014] (2) increase the propulsion rate of the small intestine or improve the peristalsis of the entire intestine;

[0015] (3) Regulate the content of colonic and gastrointestinal regulatory mediators, including motilin, gastrin, substance P, calcitonin gene-related peptide, vasoactive peptide, and nitric oxide;

[0016] (4) Reduce colon tissue damage caused by constipation;

[0017] (5) Reduce intestinal barrier damage caused by constipation, including stem cell factor, mucin 2 and occludin.

[0018] Furthermore, the laxative product includes laxative food or health care product.

[0019] Furthermore, the food includes beverages, soft candies or snacks.

[0020] Furthermore, the beverage comprises dissolving each component of the composite prebiotic in water, and then adding water to make the volume to 100 parts.

[0021] Compared with the prior art, the technical solution of the present invention has at least the following technical effects:

[0022] The composite prebiotic product of the present invention can effectively relieve constipation by repairing the intestinal barrier function under the compounding effect of various components; and the formula does not contain sorbitol, thus avoiding the side effects caused by long-term use of sorbitol for catharsis, and can be used in beverages and foods, with very valuable application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. Among them:

[0024] Figure 1 Schematic diagram showing the effect of each sample on the change of fecal water content in mice induced with loperamide to relieve constipation;

[0025] Figure 2 Schematic diagram showing the effect of each sample on the change of small intestinal propulsion rate in mice relieving constipation induced by loperamide;

[0026] Figure 3 Schematic diagram showing the effect of each sample on the change of the time to excrete the first black stool in mice induced with loperamide to relieve constipation;

[0027] Figure 4 Schematic diagram showing the effect of each sample on the change of fecal weight within 6 hours in mice induced with loperamide to relieve constipation;

[0028] Figure 5 Graph showing the effect of each sample on the change in feces quantity within 6 hours in mice with loperamide-induced constipation and mice with constipation relieved.

[0029] Figure 6 Schematic diagram of the effect of each sample on the change of the content of excitatory gastrointestinal regulatory neurotransmitter MTL in the colon of mice with constipation induced by loperamide;

[0030] Figure 7 Schematic diagram of the effect of each sample on the change of SP content in the colon of mice with loperamide-induced constipation;

[0031] Figure 8 Schematic diagram of the effect of each sample on the change of GAS content in the colon of mice with constipation induced by loperamide;

[0032] Fig. 9 Schematic diagram of the effect of each sample on the change of the content of inhibitory gastrointestinal regulatory neurotransmitter CGRP in the colon of mice with constipation induced by loperamide;

[0033] Fig.10 Schematic diagram of the effect of each sample on the change of VIP content in the colon of mice with constipation induced by loperamide;

[0034] Fig.11 Schematic diagram of the effect of each sample on the change of relative expression level of iNOS in the colon of mice with constipation induced by loperamide;

[0035] Fig.12 Schematic diagram of the effects of various samples on the changes in colon tissue of mice with loperamide-induced constipation;

[0036] Fig.13This is a schematic diagram showing the effect of each sample on the colon condition score changes of mice with loperamide-induced constipation;

[0037] Fig.14 Schematic diagram of the effect of each sample on the change of the relative expression level of SCF in the colon of mice with constipation induced by loperamide;

[0038] Fig.15 Schematic diagram of the effect of each sample on the change of relative expression level of MUC2 in the colon of mice with constipation induced by loperamide;

[0039] Fig.16 Schematic diagram of the effect of each sample on the change in the relative expression level of Occludin in the colon of mice with loperamide-induced constipation. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme in the embodiment of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention. The process parameters of the following embodiments that do not specify specific conditions are usually based on conventional conditions.

[0041] The endpoints and any values ​​of the ranges disclosed in the present invention are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be regarded as specifically disclosed in the present invention.

[0042] According to the first invention of the present invention, a composite prebiotic for relieving constipation by repairing the intestinal barrier is provided, characterized in that, by weight, it comprises the following components: 2 to 4 parts (e.g., 2, 3, 4 parts) of chicken gizzard lining, 2 to 4 parts (e.g., 2, 3, 4 parts) of hawthorn, 2 to 5 parts (e.g., 2, 3, 4, 5 parts) of prune concentrate, 2 to 4 parts (e.g., 2, 3, 4, 5 parts) of xylo-oligosaccharides, 2 to 4 parts (e.g., 2, 3, 4 parts) of stachyose, 4 parts), mannan oligosaccharides 0-0.1 parts (such as 0 parts, 0.05 parts, 0.1 parts), galacto-oligosaccharides 6-10 parts (such as 6 parts, 7 parts, 8 parts, 9 parts, 10 parts), galactomannan 0-0.1 parts (such as 0 parts, 0.05 parts, 0.1 parts), resistant dextrin 0-0.5 parts (such as 0 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts), polydextrose 0-2 parts (such as 0 parts, 1 parts, 2 parts).

[0043] Sorbitol is a sugar alcohol that is difficult to be absorbed by the human body. It can greatly increase the intestinal osmotic pressure, quickly transfer water from the internal circulation to the intestinal cavity, increase the volume and water content of stool, promote rapid intestinal peristalsis, and produce a volumetric laxative effect. Sorbitol has a strong cathartic ability and takes effect quickly, but the effect is not persistent. Long-term use of sorbitol may cause negative effects such as flatulence, colic, cramps, glucose intolerance, and intestinal flora disorders. In addition, recent studies have found that sorbitol can inhibit the development of intestinal M cells and induce cell apoptosis, thereby destroying the intestinal barrier, which may be the source of the side effects of sorbitol when used for a long time. The composite prebiotic provided by the present invention does not contain sorbitol, avoids the side effects caused by long-term use of sorbitol for catharsis, and utilizes the fact that prebiotics are not absorbed by the human body and directly reach the intestines, effectively improving the effect of intestinal flora, thereby increasing the water content and volume of stool, and by repairing the intestinal barrier function, effectively relieving constipation for a long time. The prune concentrate juice in the present invention can be a conventional commercially available product,

[0044] The weight parts of the present invention mainly include the disclosed numerical range, any numerical value (including integer and decimal) or any interval of two numerical values ​​in the disclosed range, or multiple discontinuous intervals, and also include numerical values ​​or numerical ranges close to the end value of the numerical range whose effects can be expected to be similar, such as 5-10 parts, not only including 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts and any interval of two parts, for other numerical ranges, not exemplified one by one, all are included in the present invention. Therefore, the present invention also includes the sub-range of any numerical range that has been directly disclosed or any specific numerical value therein.

[0045] In order to further optimize the effect of the composite prebiotic, the present invention studies the influence of different proportions of various components on the effect, and obtains a more optimal component ratio, which is 3 parts of chicken gizzard lining, 3 parts of hawthorn, 3.5 parts of prune concentrate, 3 parts of xylo-oligosaccharides, 3 parts of stachyose, 0.05 parts of manno-oligosaccharides, 8 parts of galacto-oligosaccharides, 0.05 parts of galacto-mannan, 0.1 parts of resistant dextrin and 1 part of polydextrose.

[0046] In the above-mentioned composite prebiotics, as a preferred embodiment, the soluble solid content in the prune concentrated juice is 60-70%.

[0047] According to a second aspect of the present invention, there is provided a use of the above-mentioned composite prebiotics in the preparation of a laxative product.

[0048] In the above scheme, as a preferred embodiment, the laxative effect includes at least one of the following functions:

[0049] (1) Increase the water content of feces;

[0050] (2) increase the propulsion rate of the small intestine or improve the peristalsis of the entire intestine;

[0051] (3) Regulate the content of colonic and gastrointestinal regulatory mediators, including motilin (MTL), gastrin (Gas), substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive peptide (VIP), and nitric oxide (NO);

[0052] (4) Reduce colon tissue damage caused by constipation;

[0053] (5) Reduce intestinal barrier damage caused by constipation, including stem cell factor (SCF), mucin 2 (MUC2), and occludin.

[0054] In the above technical solution, as a preferred implementation, the laxative product includes laxative food or health care product.

[0055] In the above technical solution, as a preferred implementation, the food includes beverages, soft candies or snacks.

[0056] In the above technical solution, as a preferred embodiment, the beverage comprises dissolving the composite prebiotics in water and then adding water to make the volume to 100 parts.

[0057] The present invention will be described in detail below in conjunction with embodiments of the present invention, and each example is provided by way of explanation of the present invention without limiting the present invention. In fact, it will be clear to those skilled in the art that modifications and variations may be made in the present invention without departing from the scope or spirit of the present invention. For example, a feature shown or described as a part of an embodiment may be used in another embodiment to produce yet another embodiment. Therefore, it is desired that the present invention includes such modifications and variations within the scope of the appended claims and their equivalents.

[0058] In the embodiments and comparative examples of the present invention, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0059] Example 1-1:

[0060] Preparation of compound prebiotic beverage

[0061] Prepare raw materials: 3g of chicken gizzard lining, 3g of hawthorn, 3.5g of prune concentrate, 3g of xylo-oligosaccharide, 3g of stachyose, 0.05g of oligomannosaccharide, 8g of galacto-oligosaccharide, 0.05g of galactomannan, 0.1g of resistant dextrin, and 1g of polydextrose; dissolve the raw materials in water and adjust the volume to 100mL to obtain the composite prebiotic beverage of the present embodiment.

[0062] Embodiment 1-2:

[0063] Preparation of compound prebiotic beverage

[0064] Prepare the raw materials: 2g of chicken gizzard lining, 2g of hawthorn, 2g of prune concentrate juice, 2g of xylo-oligosaccharide, 2g of stachyose, and 6g of galacto-oligosaccharide; dissolve the raw materials in water and adjust the volume to 100mL to obtain the composite prebiotic beverage of this embodiment.

[0065] Embodiment 1-3:

[0066] Preparation of compound prebiotic beverage

[0067] Prepare raw materials: 4g of chicken gizzard lining, 4g of hawthorn, 5g of prune concentrate, 4g of xylo-oligosaccharide, 4g of stachyose, 0.1g of oligomannosaccharide, 10g of galacto-oligosaccharide, 0.1g of galactomannan, 0.5g of resistant dextrin, and 2g of polydextrose; dissolve the raw materials in water and adjust the volume to 100mL to obtain the composite prebiotic beverage of this embodiment.

[0068] Example 2: Effect of compound prebiotic formula on alleviating slow-transit constipation in mice

[0069] Thirty 6-week-old C57BL / 6 mice (provided by Zhejiang Weitong Lihua Technology Co., Ltd.) were selected as experimental animals. The constipation model was induced by oral gavage of loperamide to form a slow-transmission constipation model. The animals were housed in an SPF animal room and fed with conventional experimental animal feed and had free access to water.

[0070] After 1 week of adaptive feeding, the mice were randomly divided into five groups: blank control group (control group), slow transit constipation model group (model group), original formula beverage group (original formula group), original formula beverage group with sorbitol added (positive group), and new formula group (composite prebiotic beverage prepared in Example 1-1). For 2 weeks of preventive intervention, the blank group and model group mice were gavaged with 0.25 mL of normal saline daily. The original formula group, positive group, and new formula group (collectively referred to as the sample group) mice were gavaged with 0.25 mL of the corresponding beverage daily.

[0071] After the preventive intervention was completed, loperamide was gavaged for one week to induce slow-transit constipation. The blank group was gavaged with 0.25 mL of normal saline, and the model group and the sample group were gavaged with 0.25 mL of 10 mg / (kg·BW) loperamide aqueous solution. One hour later, the blank group and the model group were gavaged with 0.25 mL of normal saline. The sample group was gavaged with 0.25 mL of the corresponding beverage. The mouse feces were collected daily and the number of feces within 6 hours of gavage with loperamide was recorded. The mouse feces were freeze-dried and the fecal moisture content was calculated according to the following formula.

[0072]

[0073] On the 7th day of modeling, the blank group was gavaged with 0.25 mL of saline, and the model group and sample group were gavaged with 0.25 mL of 10 mg / (kg·BW) loperamide aqueous solution. One hour later, the blank group and model group were gavaged with 0.25 mL of saline and activated carbon ink. The sample group was gavaged with 0.25 mL of the corresponding beverage and activated carbon ink. The time from the time of gavage of ink to the time of discharge of the first black stool for each mouse was recorded as the time of discharge of the first black stool.

[0074] On the evening of the 7th day of modeling, mice were fasted. After 12 hours of fasting but not water deprivation, the blank group was gavaged with 0.25 mL of saline, and the other groups were gavaged with 0.25 mL of 10 mg / (kg·BW) loperamide for modeling. Half an hour later, the blank group and the model group were gavaged with 0.25 mL of saline and activated carbon ink. The sample group was gavaged with 0.25 mL of the corresponding beverage and activated carbon ink. Half an hour later, the mice were killed, and the serum and colon of the mice were collected, and the small intestinal propulsion rate was calculated according to the following formula.

[0075]

[0076] The effects of the compound prebiotic formula on the fecal water content, small intestinal propulsion rate, time to first black stool, and fecal weight and quantity within 6 hours in mice are shown in the attached Figure 1-5 shown.

[0077] Depend on Figure 1-5 It can be seen that compared with the model group, oral administration of the new formula beverage can significantly increase the fecal water content, small intestinal propulsion rate, 6-hour fecal weight and quantity, and significantly reduce the time for mice to excrete the first black stool (p < 0.05). Specifically, the fecal water content of the new formula group increased by 15.2% compared with the model group, which is 1.56 times that of the model group. The regulatory effect of the new formula on the fecal water content increased by 26.7% compared with the original formula, and increased by 98.9% compared with the positive group. The small intestinal propulsion rate of the new formula group increased by 23.34% compared with the model group, which is 1.47 times that of the model group. The time for the first black stool in the new formula group was shortened by 103 minutes compared with the model group, which is 0.64 times that of the model group; the regulatory effect of the new formula on the time for the first black stool increased by 33.6% compared with the positive group. Compared with the model group, the stool weight of the new formula group increased by 0.19g in 6 hours, which is 2.32 times that of the model group; the stool weight of the original formula group increased by 0.01g in 6 hours compared with the model group; the regulatory effect of the new formula on the stool weight in 6 hours increased by 28.7% compared with the positive group. The number of stools in the new formula group increased by 10.4 pieces in 6 hours compared with the model group, which is 2.40 times that of the model group; the regulatory effect of the new formula on the number of stools in 6 hours increased by 333% compared with the original formula, and increased by 48.5% compared with the positive group.

[0078] It can be seen that the new formula can significantly relieve constipation, and is better than the original formula in three indicators: stool water content, 6-hour stool weight and quantity. It is also better than the original formula with sorbitol added in four indicators: stool water content, time to first black stool, 6-hour stool weight and quantity.

[0079] Example 3: Effect of compound prebiotic formula on gastrointestinal regulatory transmitters in the colon of constipated mice

[0080] The grouping, modeling and treatment of C57BL / 6 mice were the same as in Example 2. The collected colon tissue was homogenized and the contents of motilin (MTL), gastrin (Gas), substance P (SP), vasoactive peptide (VIP) and calcitonin gene-related peptide (CGRP) in the mouse colon tissue were detected using an ELISA kit. The protein concentration of colon tissue was determined using the BCA kit of Beyotime.

[0081] The mRNA in the colon tissue was extracted using an RNA extraction kit, and the mRNA was reverse transcribed into cDNA using a reverse transcription kit. The RT-qPCR experiment was performed using a qPCR kit, and the iNOS expression level was used to reflect the NO content in the colon. The gene primer sequences involved in this Example 3 are shown in Table 1:

[0082] Table 1

[0083]

[0084] Effects of compound prebiotic formula on gastrointestinal regulatory mediators in mouse colon Figure 6-11 .Depend on Figure 6-11 It can be seen that compared with the blank group, the model group had significantly decreased levels of excitatory gastrointestinal regulatory mediators MTL, GAS, and SP in the colon of mice in the model group (p < 0.05), significantly increased levels of inhibitory gastrointestinal regulatory mediators CGRP and VIP (p < 0.05), and significantly increased relative expression of iNOS (p < 0.05), indicating that loperamide-induced constipation is associated with abnormal gastrointestinal regulatory mediator content in the colon. Compared with the model group, the new formula group had significantly increased levels of excitatory gastrointestinal regulatory mediators MTL, GAS, and SP in the colon of the new formula group (p < 0.05), significantly decreased levels of inhibitory gastrointestinal regulatory mediators CGRP and VIP (p < 0.05), and significantly decreased relative expression of iNOS (p < 0.05).

[0085] Specifically, the content of excitatory gastrointestinal regulating transmitter MTL in the colon of the new formula group increased by 102.0% compared with the model group, and the regulatory effect of the new formula on the MTL content was 86.2% higher than that of the original formula. The content of excitatory gastrointestinal regulating transmitter SP in the colon of the new formula group increased by 45.7% compared with the model group, and the regulatory effect of the new formula on the SP content was 37.6% higher than that of the original formula. The content of excitatory gastrointestinal regulating transmitter GAS in the colon of the new formula group increased by 90.0% compared with the model group, and the regulatory effect of the new formula on the GAS content was 172% higher than that of the original formula. The content of inhibitory gastrointestinal regulating transmitter CGRP in the colon of the new formula group decreased by 54.3% compared with the model group, and the regulatory effect of the new formula on the CGRP content was 115% higher than that of the original formula, and 14.7% higher than that of the positive group. The content of inhibitory gastrointestinal regulating transmitter VIP in the colon of the new formula group decreased by 69.5% compared with the model group, and the regulatory effect of the new formula on the VIP content was 41.9% higher than that of the positive group. The relative expression level of iNOS in the colon of the new formula group was reduced by 54.8% compared with that of the model group.

[0086] In the intestine, MTL can promote gallbladder emptying, increase insulin release, and increase gastrointestinal motility; GAS can promote amino acid absorption and expand stomach capacity; SP can promote smooth muscle relaxation, and can also increase the sensitivity of intestinal smooth muscle to acetylcholine and promote smooth muscle contraction, thereby enhancing intestinal motility; CGRP can dilate blood vessels, reduce intestinal smooth muscle movement, and thus reduce intestinal motility; VIP can promote smooth muscle relaxation in the colon, inhibit gastric acid secretion and intestinal absorption, and weaken intestinal motility. Increased iNOS expression means increased nitric oxide content in the body. Nitric oxide in the digestive system relaxes smooth muscle and reduces intestinal motility. Increased nitric oxide content may also induce inflammation.

[0087] It can be seen that the new formula can significantly regulate the content of gastrointestinal regulatory neurotransmitters in the colon of mice and relieve the symptoms of constipation in mice. Among them, the regulatory effect on the content of MTL, GAS, SP, and CGRP in the colon of mice is stronger than the original formula, and the regulatory effect on CGRP and VIP is stronger than the original formula with sorbitol added.

[0088] Example 4: Effect of the composite prebiotic formula on colon tissue of constipated mice

[0089] C57BL / 6 mice were grouped, modeled, and treated as in Example 2. After dissection, the colon was taken and placed in 4% paraformaldehyde fixative. After soaking, it was rinsed overnight. The samples were dehydrated with gradient alcohol, washed with xylene, embedded in paraffin, sliced, and stained with HE. The sections of the mouse colon tissue were observed under a microscope and scored according to the scoring criteria in Table 2.

[0090] Table 2

[0091]

[0092] Depend on Fig.12 It can be seen that compared with the model group and the blank group (a: blank group, b: model group, c: original formula group, d: positive group, e is the new formula group), a small number of inflammatory cells can be seen in the colon of the model group (red arrow), the muscularis propria and the inter-mucosal layer are significantly thickened (blue arrow), the intestinal gland structure is abnormal (green arrow), and the number of goblet cells is reduced (yellow arrow). In the original formula group, the colon of the mice showed thickening of the muscularis propria and the inter-mucosal layer (blue arrow), abnormal intestinal gland structure (green arrow), and an increase in the number of goblet cells. In the positive group, the colon of the mice showed further thickening of the muscularis propria and the mucosa (blue arrow), an increase in the number of goblet cells, but still less (yellow arrow), and abnormal intestinal gland structure (green arrow). In the new formula group, the thickness of the muscularis propria and the inter-mucosal layer was restored, and the number of goblet cells increased.

[0093] Depend on Fig.13It can be seen that the model group was affected by constipation and the colon was damaged, while the new formula can significantly reduce the damage caused by constipation to the colon (p < 0.05). Specifically, the colon damage index of the new formula group was reduced by 63.8% compared with the model group, and the regulatory effect of the new formula on colon damage was 4.5% higher than that of the original formula, and 130% higher than that of the positive group. This shows that the new formula can reduce the damage to the intestinal glands, the reduction in the number of goblet cells, and the thickening of the muscularis propria or submucosal layer in the colon tissue of constipated mice, and significantly alleviate the impact of constipation on the intestinal barrier. The new formula is better than the original formula and the original formula with sorbitol added.

[0094] Example 5: Complex prebiotic formula relieves constipation by repairing the intestinal barrier

[0095] C57BL / 6 mice were grouped, modeled, and treated as in Example 2. mRNA in colon tissue was extracted using an RNA extraction kit, and mRNA was reverse transcribed into cDNA using a reverse transcription kit. RT-qPCR experiments were performed using a qPCR kit. The gene primer sequences involved in the example are shown in Table 3.

[0096] Table 3

[0097]

[0098]

[0099] Effects of compound prebiotic formula on mRNA expression in mouse colon Figure 14-16 .Depend on Figure 14-16 It can be seen that compared with the blank group, the expression of stem cell factor (SCF), mucin 2 (MUC2), and occludin in the colon of mice in the model group decreased significantly (p < 0.05), indicating that loperamide-induced constipation destroyed the intestinal barrier. Compared with the model group, the relative expression of SCF, MUC2, and Occludin in the colon of mice in the new formula group increased significantly (p < 0.05), indicating that the prebiotic compound formula can alleviate the intestinal barrier damage caused by constipation.

[0100] Specifically, the relative expression level of SCF in the colon of the new formula group increased by 81.2% compared with the model group, increased by 97.2% compared with the original formula group, and increased by 74.1% compared with the positive group; the relative expression level of MUC2 in the colon of the new formula group increased by 155% compared with the model group, and increased by 237% compared with the original formula group, and the regulatory effect of the new formula on the relative expression level of MUC2 in the colon was increased by 34.8% compared with the positive group; the relative expression level of Occludin in the colon of the new formula group increased by 224% compared with the model group, and increased by 136% compared with the original formula group, and the regulatory effect of the new formula on the relative expression level of Occludin was increased by 152% compared with the positive group.

[0101] It is reported that SCF is essential for the normal development and maturation of interstitial cells of Cajal. Interstitial cells of Cajal are a type of nerve cells distributed in the submucosal layer and the muscularis propria, which control intestinal pacemaking. The reduction in SCF expression means that the intestinal barrier is damaged and the function of interstitial cells of Cajal is weakened; Occludin is an intercellular tight junction protein, and its expression is positively correlated with the strength of the intestinal mechanical barrier; MUC2 is a mucin secreted by intestinal glands, and its expression is positively correlated with the strength of the intestinal mucus layer and the number of goblet cells; the reduction in the expression of SCF, Occludin and MUC2 may indicate that constipation causes impaired intestinal barrier function, and the recovery of expression indicates that the new formula can alleviate the damage of intestinal barrier function caused by constipation. Constipation destroys the intestinal barrier, and the new formula can significantly repair the intestinal barrier damage caused by constipation. The three indicators of SCF, Occludin and MUC2 all show that the regulatory effect of the new formula on intestinal barrier function is significantly better than the original formula and the positive group.

[0102] In the above experiments on mice, the comparison between the model group and the blank group was: #: p<0.05, ##: p<0.01, ###: p<0.005; the comparison between the original formula group, the positive group, the new formula group and the model group was: *: p<0.05, **: p<0.01, ***: p<0.005.

[0103] In summary, the prebiotic compound formula of the present invention can significantly relieve constipation. The new formula can significantly improve the fecal moisture content, small intestinal propulsion rate, 6-hour fecal weight and quantity, and significantly reduce the time for mice to excrete the first black stool (p < 0.05). The new formula has a 26.7% higher regulatory effect on fecal moisture content than the original formula, and a 98.9% higher effect than the original formula with sorbitol added (hereinafter referred to as the positive group). The new formula has a 33.6% higher regulatory effect on the time to the first black stool than the positive group. The new formula has a 28.7% higher regulatory effect on the 6-hour fecal weight than the positive group. The new formula has a 333% higher regulatory effect on the 6-hour fecal quantity than the original formula, and a 48.5% higher effect than the positive group. In summary, the new formula has a better regulatory effect on the three indicators of fecal moisture content, 6-hour fecal weight and quantity than the original formula, and the new formula has a better regulatory effect on the four indicators of fecal moisture content, first black stool time, 6-hour fecal weight and quantity than the positive group.

[0104] The prebiotic compound formula of the present invention can significantly regulate the content of gastrointestinal regulatory transmitters in the colon of mice. The new formula can significantly increase the content of excitatory gastrointestinal regulatory transmitters MTL, GAS, and SP in the colon (p < 0.05), and can significantly reduce the content of inhibitory gastrointestinal regulatory transmitters CGRP, VIP, and NO in the colon (p < 0.05). The new formula has an 86.2% higher regulatory effect on the MTL content than the original formula. The new formula has an 37.6% higher regulatory effect on the SP content than the original formula. The new formula has an 172% higher regulatory effect on the GAS content than the original formula. The new formula has an 115% higher regulatory effect on the CGRP content than the original formula, and an increase of 14.7% compared to the positive group. The new formula has an 41.9% higher regulatory effect on the VIP content than the positive group. In summary, the new formula has a stronger regulatory effect on the MTL, GAS, SP, and CGRP content in the colon of mice than the original formula. The new formula has a stronger regulatory effect on CGRP and VIP than the positive group.

[0105] The prebiotic compound formula of the present invention can significantly alleviate the impact of constipation on colon tissue, and the new formula can significantly alleviate colon damage (p < 0.05). The new formula has a 4.5% higher regulatory effect on colon damage than the original formula, and a 130% higher effect than the positive group. The new formula is more effective in alleviating colon damage than the original formula and the positive group.

[0106] The prebiotic compound formula of the present invention can significantly alleviate the intestinal barrier damage caused by constipation in mice. The new formula can significantly increase the expression of SCF, MUC2, and Occludin in the colon of mice (p < 0.05). The relative expression of SCF in the colon of the new formula group increased by 97.2% compared with the original formula group, and increased by 74.1% compared with the positive group; the relative expression of MUC2 increased by 237% compared with the original formula group, and the regulatory effect of the new formula on the relative expression of MUC2 in the colon increased by 34.8% compared with the positive group; the relative expression of Occludin in the colon of the new formula group increased by 136% compared with the original formula group, and the regulatory effect of the new formula on the relative expression of Occludin increased by 152% compared with the positive group. In summary, the effect of the new formula in repairing intestinal barrier damage is significantly stronger than the original formula and the positive group.

[0107] Therefore, the prebiotic compound formula of the present invention can effectively relieve constipation. The new formula is superior to the original formula and the original formula with sorbitol added in most indicators. The new formula has excellent effect in repairing the intestinal barrier, which is much stronger than the original formula and the positive group. It can be seen that the prebiotic compound formula provided by the present invention is an excellent formula, which can be used in foods such as beverages and has a very valuable application prospect.

[0108] The above describes and evaluates the efficacy of some embodiments of the present invention. It should be understood that the present invention is not limited to the above specific implementations. Any technician familiar with the art can use the above disclosed methods and technical contents to make many possible changes and modifications to the technical solutions of the present invention without departing from the scope of the technical solutions of the present invention, or modify them into equivalent embodiments of equivalent changes, which does not affect the essential content of the present invention. Therefore, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solutions of the present invention still falls within the scope of protection of the technical solutions of the present invention.

Claims

1. A composite prebiotic, characterized in that: The invention comprises the following components by weight: 2-4 parts of chicken's gizzard lining, 2-4 parts of hawthorn, 2-5 parts of prune concentrate, 2-4 parts of xylo-oligosaccharide, 2-4 parts of stachyose, 0-0.1 parts of manno-oligosaccharide, 6-10 parts of galacto-oligosaccharide, 0-0.1 parts of galacto-mannan, 0-0.5 parts of resistant dextrin and 0-2 parts of polydextrose.

2. The composite prebiotic according to claim 1, characterized in that The invention comprises the following components by weight: 3 parts of chicken's gizzard lining, 3 parts of hawthorn, 3.5 parts of prune concentrate, 3 parts of xylo-oligosaccharide, 3 parts of stachyose, 0.05 parts of manno-oligosaccharide, 8 parts of galacto-oligosaccharide, 0.05 parts of galacto-mannan, 0.1 parts of resistant dextrin and 1 part of polydextrose.

3. The composite prebiotic according to claim 1 or 2, characterized in that: The soluble solid content in the prune concentrated juice is 60-70%.

4. Use of the composite prebiotic according to any one of claims 1 to 3 in the preparation of a laxative product.

5. The use according to claim 4, characterized in that: The laxative function includes at least one of the following: (1) Increase the water content of feces; (2) increase the propulsion rate of the small intestine or improve the peristalsis of the entire intestine; (3) Regulate the content of colonic and gastrointestinal regulatory mediators, including motilin, gastrin, substance P, calcitonin gene-related peptide, vasoactive peptide, and nitric oxide; (4) Reduce colon tissue damage caused by constipation; (5) Reduce intestinal barrier damage caused by constipation, including stem cell factor, mucin 2 and occludin.

6. The use according to claim 5, characterized in that: The intestinal moistening and laxative products include intestinal moistening and laxative foods or health products.

7. The use according to claim 6, characterized in that: The food includes beverages, soft candies or snacks.

8. The use according to claim 7, characterized in that: The beverage comprises dissolving the components of the composite prebiotics in water, and then adding water to make the volume to 100 parts.